<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features, evaluation, and management of fever in patients with impaired splenic function</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features, evaluation, and management of fever in patients with impaired splenic function</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical features, evaluation, and management of fever in patients with impaired splenic function</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Pasternack, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fever in a patient with impaired splenic function is a warning sign for possible sepsis and should be treated as a medical emergency. Asplenic and functionally hyposplenic patients are at risk for severe and overwhelming infections with encapsulated bacteria (eg, <em>Streptococcus pneumoniae)</em>, bloodborne parasites, and other infections that the spleen plays an important role in controlling. Infection with these pathogens can be rapidly fatal, and immediate empiric antibiotic administration is critical to care.</p><p>The clinical features, common causes, and management of sepsis in the asplenic patient will be reviewed here. The prevention of sepsis in the asplenic patient is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ROLE OF THE SPLEEN IN INFECTION</span><span class="headingEndMark"> — </span>The spleen plays a central role in clearing pathogens from the bloodstream and controlling infections, particularly with encapsulated bacteria. Within the red pulp of the spleen, sinusoids serve as mechanical filters that remove rigid particles &gt;1 micron in size from circulation, including senescent and/or parasitized red blood cells, and unopsonized bacteria  (<a class="graphic graphic_figure graphicRef122441" href="/z/d/graphic/122441.html" rel="external">figure 1</a>) [<a href="#rid1">1,2</a>]. Macrophages, positioned along the sinusoids, eliminate some infected cells or bacteria via phagocytosis and also produce proinflammatory cytokines in response to infection [<a href="#rid3">3</a>]. The white pulp of the spleen houses approximately half of the body's immunoglobulin-producing B lymphocytes, which are critical for producing antibodies that target polysaccharide antigens on the surface of encapsulated bacteria.</p><p class="headingAnchor" id="H1304887166"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Both anatomic and functional asplenia and hyposplenism predispose to infection  (<a class="graphic graphic_table graphicRef119147" href="/z/d/graphic/119147.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Asplenia refers to complete loss of function of the spleen and may be anatomic or functional. Anatomic asplenia is most often due to surgical splenectomy, performed for trauma or therapeutically (eg, for hemolytic anemias or immune thrombocytopenias) [<a href="#rid4">4</a>]. Functional asplenia refers to complete loss of function caused by medical conditions and occurs most frequently with sickle cell anemia [<a href="#rid5">5</a>]. Rarely, the spleen is congenitally absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyposplenism refers to partial loss of splenic function and is most often caused by medical disorders that lead to atrophy, infarction, engorgement, or infiltration of the spleen, such as thalassemias, chronic liver disease, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), immune disorders, or malignancies [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Asplenia or hyposplenia'</a>.)</p><p></p><p class="headingAnchor" id="H1380434546"><span class="h1">RISK OF SEVERE INFECTION</span><span class="headingEndMark"> — </span>The risks of infection, sepsis, and sepsis-related mortality appear to be approximately two to three times higher in asplenic patients when compared with the general population [<a href="#rid6">6,7</a>]. In a cohort study evaluating over 8000 splenectomized patients over a 27-year period, splenectomized patients had increased rates of sepsis (rate ratio [RR] 3.38, 95% CI 3.12-3.67) and sepsis-related mortality (RR 3.02, 95% CI 1.80-5.06) when compared with matched controls [<a href="#rid7">7</a>]. The increased risk for sepsis and sepsis-related mortality were sustained over a 10-year period and are presumed to be lifelong [<a href="#rid8">8</a>]. Because these studies included patients using antibiotic prophylaxis, the actual risk of infection is likely higher. </p><p>Among patients with impaired splenic function, higher rates of infection have been observed in children and older adults [<a href="#rid9">9-11</a>]. Patients with asplenia or hyposplenism related to hemoglobinopathies, hematologic malignancies, immunodeficiencies, and inflammatory diseases (eg, systemic lupus erythematosus) have been reported to have higher rates of severe infections when compared with patients who have undergone splenectomy for trauma [<a href="#rid9">9,11-15</a>]. However, these associations have not been consistently observed across studies [<a href="#rid7">7,11</a>].</p><p>Asplenic patients with a history of severe infections appear to be predisposed to having subsequent episodes [<a href="#rid9">9</a>]. In a retrospective review of over 1600 splenectomized patients, the incidence of severe infection was sixfold higher among patients with a history of severe infection compared with patients without such history [<a href="#rid9">9</a>]. Among asplenic patients, lack of vaccination against encapsulated organisms, such as <em>S. pneumoniae</em>, also raises the likelihood of severe infection [<a href="#rid13">13,16</a>].</p><p class="headingAnchor" id="H1686637464"><span class="h1">FEVER AND OVERWHELMING SEPSIS</span></p><p class="headingAnchor" id="H487517679"><span class="h2">Identifying patients at risk</span><span class="headingEndMark"> — </span>We generally consider all patients with anatomic asplenia at risk for severe and overwhelming sepsis  (<a class="graphic graphic_table graphicRef119147" href="/z/d/graphic/119147.html" rel="external">table 1</a>).</p><p>Determining the risk of severe infection and overwhelming sepsis among patients with functional splenic loss is less straightforward. Because this risk is not equal among patients with functional hyposplenism, we generally individualize our approach to management.</p><p>We favor treating patients with functional asplenia or hyposplenism similarly to patients with anatomic asplenia when they present with severe illnesses (eg, sepsis) or when they have a history of recurrent bacterial infections and/or when testing results suggest loss of splenic function (eg, presence of Howell-Jolly bodies on blood smear  (<a class="graphic graphic_picture graphicRef60588" href="/z/d/graphic/60588.html" rel="external">picture 1</a>) or low number of circulating immunoglobulin [Ig]M memory B cells).</p><p>The best method for assessing splenic function is not established. When splenic function is in doubt, we typically obtain a peripheral blood smear to assess for Howell-Jolly bodies. Their presence correlates with impaired splenic function  (<a class="graphic graphic_picture graphicRef60588" href="/z/d/graphic/60588.html" rel="external">picture 1</a>) and serves as a useful screen for clinically significant dysfunction and risk of sepsis [<a href="#rid17">17,18</a>]. Volumetric assessment of the spleen can be performed with Tc<sup>99m</sup> sulfur colloid liver-spleen scintigraphy and SPECT imaging [<a href="#rid19">19</a>], and functional assessment can be achieved using Tc<sup>99m</sup> labeled heat-treated autologous erythrocytes followed by scintigraphy and multimodality SPECT imaging [<a href="#rid20">20</a>]. Quantitation of erythrocyte pitting, another measure of splenic functional assessment, can be performed using interference contrast microscopy [<a href="#rid20">20</a>]. The latter two assays are not necessarily routinely available and have not been compared in large populations of patients with impaired splenic function to assess test sensitivity and specificity. In some institutions, additional testing options are available, such as quantification of memory B cells by flow cytometry. However, the best method for assessing splenic function has not been determined. (See  <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Asplenia or hyposplenia'</a>.)</p><p class="headingAnchor" id="H1206289610"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Fever in a patient with impaired splenic function should be interpreted as an early sign of sepsis. Without prompt and appropriate treatment, infections in asplenic and hyposplenic patients can become fulminant and fatal within hours of symptom onset [<a href="#rid21">21-24</a>].</p><p>The most common foci of infection accompanying sepsis in asplenic and hyposplenic patients are pneumonia, primary bacteremia, and meningitis [<a href="#rid10">10,13</a>]. Signs and symptoms of these infections can be nonspecific in early illness and include chills, malaise, headache, and gastrointestinal complaints (eg, nausea, vomiting, diarrhea, and abdominal pain) [<a href="#rid21">21</a>].</p><p>Fulminant sepsis has been reported to quickly follow even minor complaints and can also develop precipitously without specific antecedent symptoms [<a href="#rid22">22,25</a>]. As illness progresses, high-grade bacteremia, hypotension, endovascular injury, and disseminated intravascular coagulation can ensue, leading to the development of purpura fulminans, extremity gangrene, and even autoamputation [<a href="#rid26">26-28</a>]. Metastatic infection (eg, septic arthritis, meningitis, or pericarditis) may also become evident.</p><p>While the dominant characteristic of sepsis in patients with impaired splenic function is its rapid progression, certain clinical and/or epidemiologic features raise suspicion for specific pathogens  (<a class="graphic graphic_table graphicRef119148" href="/z/d/graphic/119148.html" rel="external">table 2</a>). (See <a class="local">'Important pathogens'</a> below.)</p><p class="headingAnchor" id="H2113468893"><span class="h2">Important pathogens</span><span class="headingEndMark"> — </span>Fulminant sepsis in patients with impaired splenic function is most often caused by encapsulated bacteria, including <em>S. pneumoniae</em>, <em>Haemophilus influenzae</em>, and <em>Neisseria meningitidis</em>. Other bacterial pathogens, including <em>Capnocytophaga canimorsus</em> and more common bacteria such as <em>Klebsiella pneumoniae,</em> can provoke similar syndromes of fulminant sepsis. Infections caused by bloodborne parasites, such as malaria and babesiosis, can also be particularly severe in asplenic patients  (<a class="graphic graphic_table graphicRef119148" href="/z/d/graphic/119148.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H80423184"><span class="h3">Encapsulated bacteria</span></p><p class="headingAnchor" id="H4189842594"><span class="h4">Streptococcus pneumoniae (pneumococcus)</span><span class="headingEndMark"> — </span>The single most important pathogen is <em>S. pneumoniae</em>. This organism accounts for approximately 40 to 60 percent of cases of severe infection and overwhelming sepsis in splenectomized patients [<a href="#rid10">10,13,14</a>]. Although the overall incidence of <em>S. pneumoniae</em> infections is declining because of widespread pneumococcal vaccination [<a href="#rid29">29,30</a>], patients with impaired splenic function are still at higher risk for <em>S. pneumoniae</em> infection and poorer outcomes when compared with patients who have normal splenic function [<a href="#rid13">13,16,31</a>]. In a prospective cohort study evaluating over 2400 patients with invasive pneumococcal disease, asplenic patients were more likely to have meningitis (22 versus 5 percent), require intensive care unit admission (51 versus 28 percent), and require mechanical ventilation (41 versus 22 percent) [<a href="#rid31">31</a>]. In-hospital mortality was higher in asplenic patients when compared with patients with spleens (18.9 versus 15.6 percent); however, this difference was not statistically significant.</p><p>The clinical syndromes associated with <em>S. pneumoniae</em> infection in patients with impaired splenic functions are similar to those seen in other patients and include pneumonia, bacteremia, and meningitis. Initial symptoms can be nonspecific (eg, fever, rigors, malaise, nausea, vomiting, and diarrhea) but progress to severe sepsis within hours [<a href="#rid21">21</a>]. In keeping with the increased severity of illness observed in asplenic patients, purpura fulminans appears to be more common in asplenic patients with pneumococcal infections when compared with patients who have normal splenic function [<a href="#rid13">13</a>]. Clinical features of <em>S. pneumoniae </em>infections are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3168.html" rel="external">"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7013.html" rel="external">"Pneumococcal pneumonia in patients requiring hospitalization"</a>.)</p><p class="headingAnchor" id="H383072257"><span class="h4">Haemophilus influenzae type b</span><span class="headingEndMark"> — </span><em>H. influenzae </em>type b was previously among the more common causes of sepsis in patients with impaired splenic function, but its incidence has declined sharply with widespread use of the conjugate <em>H. influenzae </em>type b vaccine [<a href="#rid10">10,11,13</a>]. Clinical syndromes associated with severe <em>H. influenzae</em> type b infections include pneumonia, bacteremia, and meningitis. (See  <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of <i>Haemophilus influenzae</i>", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H1359555203"><span class="h4">Neisseria meningitidis (meningococcus)</span><span class="headingEndMark"> — </span><em>N. meningitidis </em>is a less common cause of severe and overwhelming infections in patients with impaired splenic function, accounting for &lt;3 percent of reported cases [<a href="#rid10">10</a>]. Whether it is more prevalent in patients with impaired splenic function than in the general population is not clear [<a href="#rid32">32</a>]. The primary clinical syndromes associated with <em>N. meningitidis </em>infection are meningitis and meningococcemia. Even among patients with normal splenic function, early symptoms of meningococcal disease can be nonspecific and "flu-like" followed by rapid progression to septic shock, which is frequently accompanied by disseminated intravascular coagulation and purpura fulminans. (See  <a class="medical medical_review" href="/z/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a>.)</p><p class="headingAnchor" id="H3388053823"><span class="h4">Other encapsulated bacteria</span><span class="headingEndMark"> — </span>Other encapsulated bacteria that have been reported to cause severe and overwhelming sepsis in asplenic patients include <em>Capnocytophaga</em> species, <em>Bordetella holmesii </em>(which is putatively encapsulated), and <em>K. pneumoniae </em>[<a href="#rid33">33-36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Capnocytophaga </em></strong><strong>spp</strong> –<em> C. canimorsus</em> and, less commonly, <em>C. cynodegmi</em> are transmitted to humans primarily via dog bites [<a href="#rid36">36-39</a>]. Approximately 12 percent of reported cases of infection with these organisms occur in asplenic patients [<a href="#rid38">38</a>]. The primary clinical syndromes associated with <em>Capnocytophaga</em> infections include sepsis, meningitis, cellulitis, purpura fulminans, and gangrene. The associated mortality among asplenic patients is approximately 30 percent [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/98717.html" rel="external">"Capnocytophaga"</a> and  <a class="medical medical_review" href="/z/d/html/98717.html" rel="external">"Capnocytophaga", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Bordetella holmesii</em></strong> – <em>B. holmesii</em> is a respiratory pathogen that primarily causes pertussis-like symptoms in immunocompetent persons; however, knowledge of this organism is limited [<a href="#rid34">34,40-42</a>]. Among immunocompromised patients, extrapulmonary and invasive infections have been reported largely in patients with impaired splenic function and include cellulitis, septic arthritis, sepsis, pericarditis, and endocarditis [<a href="#rid35">35,42-44</a>]. While these infections can be severe among asplenic patients, fatal cases have not been reported [<a href="#rid44">44</a>]. The incidence of severe <em>B. holmesii</em> infections appears to correlate with pertussis outbreaks.</p><p></p><p>Infections with <em>K.</em> <em>pneumoniae</em> do not appear to be more common in patients with impaired splenic function when compared with patients with normal splenic function but can be rapidly progressive and fatal [<a href="#rid13">13,33,45</a>].</p><p class="headingAnchor" id="H4244346351"><span class="h3">Bloodborne parasites</span><span class="headingEndMark"> — </span><em>Babesia </em>and <em>Plasmodium</em> parasites invade red blood cells, and clearance of infection with these organisms is reduced in patients with impaired splenic function.</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Babesia</em></strong><strong> spp</strong> – Babesiosis is a tickborne illness characterized by fever, malaise, myalgias, arthralgias, and hemolytic anemia. Patients with impaired splenic function are at risk for high-grade parasitemia and severe infection, which can progress to acute respiratory distress syndrome, multiorgan failure, and disseminated intravascular coagulation [<a href="#rid46">46,47</a>]. Persistent and relapsing babesiosis appears to be more common among patients with impaired splenic function [<a href="#rid48">48</a>]. Fatal cases are uncommon but have been reported [<a href="#rid49">49,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/5670.html" rel="external">"Babesiosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Most cases occur in coastal New England during the warmer months when tick activity is high. However, babesiosis occurs sporadically in other regions of the United States as well as in Europe, Asia, and Australia. Babesiosis can also be transfusion transmitted and has been confused with hemolytic transfusion reactions leading to delayed diagnosis among asplenic patients with hemoglobinopathies [<a href="#rid51">51-53</a>]. (See  <a class="medical medical_review" href="/z/d/html/5734.html" rel="external">"Babesiosis: Microbiology, epidemiology, and pathogenesis", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Plasmodium</em></strong><strong> spp</strong> – <em>Plasmodium</em> parasites are the causative agents of malaria. The presence of fever should raise suspicion for malaria in patients who have recently traveled to or live in areas where malaria is endemic (ie, most tropical regions of the world, especially sub-Saharan Africa). Additional clinical features vary based on the infecting <em>Plasmodium</em> species and immune status of the patient. (See  <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a>.)</p><p></p><p class="bulletIndent1">The degree to which asplenia or hyposplenism alters the course of malaria is unclear. Patients with impaired splenic function who have not been previously exposed to malaria may have prolonged fever, persistent parasitemia, and delayed responses to therapy due to the loss of splenic filtration [<a href="#rid54">54,55</a>]. Severe and fatal infections have also been reported [<a href="#rid54">54,56</a>]. In contrast, immune individuals who are reinfected following splenectomy appear to have a typical mild course of infection, suggesting that the spleen is not required for the immune sequestration of infected erythrocytes [<a href="#rid57">57</a>].</p><p></p><p class="headingAnchor" id="H271067012"><span class="h3">Other pathogens</span><span class="headingEndMark"> — </span><em>Staphylococcus aureus</em>, <em>Escherichia coli</em>, and other pathogens that commonly cause bacteremia have been reported to cause overwhelming infections in patients with impaired splenic function [<a href="#rid10">10,11,13</a>]. Cytomegalovirus [<a href="#rid58">58,59</a>], <em>Mycoplasma pneumoniae</em> [<a href="#rid60">60</a>], <em>Mycobacterium tuberculosis </em>[<a href="#rid61">61</a>], and <em>Ehrlichia</em> species [<a href="#rid62">62</a>] have also been reported to cause unusually severe or fatal infections among asplenic patients. However, whether splenic impairment is truly a risk factor for infection with these pathogens is not established.</p><p class="headingAnchor" id="H14"><span class="h1">EVALUATION AND MANAGEMENT</span></p><p class="headingAnchor" id="H885446057"><span class="h2">Initial triage and management</span><span class="headingEndMark"> — </span>Immediate empiric antibiotic administration and aggressive supportive care are crucial for the management of sepsis in patients with impaired splenic function [<a href="#rid5">5,63,64</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>We advise all asplenic and hyposplenic patients who develop fever to take an oral antibiotic (if on hand) AND present to the nearest emergency department immediately  (<a class="graphic graphic_table graphicRef119181" href="/z/d/graphic/119181.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef119183" href="/z/d/graphic/119183.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Emergency antibiotic supply'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upon arrival to the emergency department, we recommend starting empiric intravenous broad-spectrum antibiotics immediately  (<a class="graphic graphic_table graphicRef119150" href="/z/d/graphic/119150.html" rel="external">table 5</a>). Administration of antibiotics should <strong>not</strong> be delayed in order to perform diagnostic studies, including lumbar puncture. (See <a class="local">'Empiric antibiotic selection'</a> below.)</p><p></p><p>Because progression to septic shock and respiratory distress can occur rapidly, preparations for fluid resuscitation, vasopressor support, and airway management should be made. (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a> and  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)"</a>.)</p><p>Generally, we admit asplenic and hyposplenic patients with fever and/or sepsis to the hospital for at least 72 hours for close monitoring, supportive care, and empiric antibiotic treatment while the diagnostic evaluation is pending.</p><p class="headingAnchor" id="H1195588514"><span class="h2">Initial diagnostic evaluation</span><span class="headingEndMark"> — </span>As with other patients with sepsis, the initial evaluation should be directed at assessing the severity of infection and identifying its source. In addition to a thorough history (including past immunizations) and physical examination, we generally include or consider the following tests or procedures in our evaluation  (<a class="graphic graphic_table graphicRef119151" href="/z/d/graphic/119151.html" rel="external">table 6</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine laboratory tests</strong> – Laboratory testing is similar to other patients with sepsis (eg, complete blood count with differential, comprehensive metabolic panel, coagulation studies, and lactate). We also send an arterial or venous blood gas for patients with signs of hemodynamic instability.</p><p></p><p class="bulletIndent1">Like other septic patients, the white blood cell count may be elevated or markedly depressed. An elevated creatinine and hepatic transaminases may signify the onset of multiorgan dysfunction. In asplenic patients, progression to disseminated intravascular coagulation (DIC) often occurs early in the course of illness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral blood smear</strong> – The peripheral smear usually demonstrates a marked left shift with bands and early myeloid forms. Blood smears also demonstrate Howell-Jolly bodies  (<a class="graphic graphic_picture graphicRef60588" href="/z/d/graphic/60588.html" rel="external">picture 1</a>), reflecting the loss of splenic function. Intracellular or extracellular bacteria can occasionally be visualized directly on the peripheral blood smear or via Gram or Wright stain on the white cell buffy coat, reflecting high-grade bacteremia  (<a class="graphic graphic_picture graphicRef50416" href="/z/d/graphic/50416.html" rel="external">picture 2</a>) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quantitative immune globulins</strong> – In addition to the laboratory tests outlined above, some UpToDate authors and editors send a quantitative immunoglobulin G level because adjunctive therapy with intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) may be warranted in patients with low levels and other selected patients. (See <a class="local">'Intravenous immune globulin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood cultures</strong> – Blood cultures should be obtained before the start of antibiotics, when feasible. Cultures can be obtained when intravenous (IV) access is established to avoid further delay in the administration of parenteral antibiotic therapy. Because of the high bacterial loads in asplenic and hyposplenic patients, cultures may turn positive within hours of inoculation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronavirus disease 2019 (COVID-19) testing –</strong> During the pandemic, we test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in all patients with fever. (See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other microbiologic testing</strong> – Because of the high rates of pneumococcal infection in asplenic and hyposplenic patients, we obtain urine <em>S. pneumoniae </em>antigen testing in adults in addition to blood cultures. Additional microbiologic testing (eg, sputum, urine, throat, and/or cerebrospinal fluid [CSF] culture) should be obtained based on the suspected site of infection and individual patient risk or epidemiologic risk factors (eg, testing for seasonal influenza). Cutaneous lesions can also be aspirated for Gram stain and culture. Blood pneumococcal and/or meningococcal polymerase chain reaction may be available at some institutions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Chest radiographs are warranted in nearly all patients due to increased likelihood of pneumonia. Other imaging tests should be obtained based on the suspected sites of infection (eg, sinus or abdominal computed tomography scan).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lumbar puncture</strong> – Our threshold for obtaining a lumbar puncture is low in patients with impaired splenic function because of their increased risk for bacterial meningitis. We usually perform a lumbar puncture in patients with nonlocalizing neurologic dysfunction who have normal platelets and coagulation studies. However, it is common for lumbar puncture to be deferred because of the development of DIC. For patients who do undergo lumbar puncture, a normal or only slightly abnormal CSF profile does not necessarily rule out bacterial meningitis. Patients may become ill so quickly that characteristic changes (eg, marked neutrophilic pleocytosis) may not be observed early in the course of meningitis.</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Empiric antibiotic selection</span></p><p class="headingAnchor" id="H1315915163"><span class="h3">Standard regimen</span><span class="headingEndMark"> — </span>For most asplenic and hyposplenic adults and children who present with fever and/or other signs of sepsis, we select an empiric antibiotic regimen that includes coverage for <em>S. pneumoniae, H. influenzae</em> type b, and <em>N. meningitidis </em> (<a class="graphic graphic_table graphicRef119150" href="/z/d/graphic/119150.html" rel="external">table 5</a>). Because of the increased prevalence of meningitis among these patients, we dose these antibiotics for CSF penetration.</p><p class="bulletIndent1"><span class="glyph">●</span>For most asplenic and hyposplenic adults and children with fever and/or known or suspected sepsis, we treat with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> <strong>plus</strong> either <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> <strong>or</strong> <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For asplenic and hyposplenic adults in whom meningitis is strongly suspected based on clinical features (eg, fever, headache, altered mental status, and neck stiffness), we typically give adjunctive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> at the time of antibiotic administration. For children with suspected bacterial meningitis, we decide when to use adjunctive dexamethasone on a case-by-case basis. (See <a class="local">'Dexamethasone for meningitis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For selected asplenic and hyposplenic patients with severe sepsis, disseminated intravascular coagulation, or for those with additional immunocompromising conditions, we often give intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> in addition to antibiotics. (See <a class="local">'Intravenous immune globulin'</a> below.)</p><p></p><p>Modifications to this regimen may be needed for patients with risk factors for other infections that may be particularly severe in patients with impaired splenic function, such as animal bites or travel to regions where malaria is endemic. (See <a class="local">'Unusual exposures'</a> below.)</p><p>As with any septic patient, additional adjustments to the empiric antibiotic regimen may be needed based on the suspected source of infection, relevant exposures, risk of infection with antibiotic-resistant pathogens, patient comorbidities, and other factors. (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Empiric antibiotic therapy (first hour)'</a> and  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Empiric antibiotic therapy'</a>.)</p><p>Our antibiotic recommendations are based on knowledge of the pathogens that are most likely to cause sepsis in patients with impaired splenic function and their antimicrobial resistance patterns. <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> and <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> are both active against most <em>S. pneumoniae</em>, <em>H. influenzae </em>type b, and <em>N. meningitidis </em>isolates. <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> is added to the regimen to treat potential beta-lactam-resistant <em>S. pneumoniae</em>. Controlled trials evaluating treatment regimens in this patient population have not been performed.</p><p class="headingAnchor" id="H2886363926"><span class="h3">Penicillin and cephalosporin allergy</span><span class="headingEndMark"> — </span>The main alternatives to cephalosporins include an extended-spectrum fluoroquinolone (eg, <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>) and <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>  (<a class="graphic graphic_table graphicRef119150" href="/z/d/graphic/119150.html" rel="external">table 5</a>). Selection among these agents depends on the type of drug reaction  (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 7</a>), patient age, and severity of illness.</p><p class="bulletIndent1"><span class="glyph">●</span>For most asplenic and hyposplenic adults who have a history of an IgE-mediated reaction or a serious delayed reaction to penicillins and/or cephalosporins, we treat empirically with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most asplenic and hyposplenic children who have a history of an IgE-mediated reaction or a serious delayed reaction to penicillins and/or cephalosporins  (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 7</a>), we treat empirically with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>. While <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> has greater activity against many of the pathogens that commonly cause meningitis in asplenic patients and has been tolerated among children treated for drug-resistant tuberculosis, experience in treating bacterial meningitis in children with moxifloxacin is limited. A dose of 5 mg/kg IV every 24 hours was used in a case report in a neonate with meningitis [<a href="#rid65">65</a>], and a subsequent study suggests that moxifloxacin may be well tolerated in children [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">Following the first dose of antibiotics, we generally consult an allergist to determine whether the patient can be transitioned to a cephalosporin or carbapenem following a test dose procedure or if skin testing and/or desensitization is needed and/or recommended. (See  <a class="medical medical_review" href="/z/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a> and  <a class="medical medical_review" href="/z/d/html/13535.html" rel="external">"Cephalosporin hypersensitivity: Clinical manifestations and diagnosis"</a>.)</p><p></p><p>An alternate approach for adults and children who have a history of IgE-mediated reactions to penicillin or cephalosporins or mild delayed reactions to cephalosporins is to treat with <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>. This approach is preferred by some experts, particularly for patients with meningitis and/or severe sepsis because the likelihood of cross-reactivity is low and meropenem has greater activity against the pathogens that commonly cause severe infections in patients with impaired splenic function.</p><p>Adults and children with a history of a mild, non-IgE-mediated reaction to penicillins can generally tolerate cephalosporins, and we treat these patients with the standard regimen outlined above. (See <a class="local">'Standard regimen'</a> above.)</p><p class="headingAnchor" id="H4005761099"><span class="h3">Unusual exposures</span><span class="headingEndMark"> — </span>Impaired splenic function is an important risk factor for overwhelming infection with <em>Capnocytophaga</em> species<em>, </em>which is typically transmitted by dog bites, but scratches and animals other than dogs can also be a source. Infections with bloodborne parasites, such as babesiosis and malaria, can also be particularly severe in patients with impaired splenic function. While infections with these pathogens are overall uncommon in asplenic patients, early diagnosis and appropriate treatment can improve outcomes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Animal bites - </strong>For asplenic and hyposplenic patients with an antecedent dog bite (or other animal bite), we treat with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus a beta-lactam-beta-lactamase inhibitor combination antibiotic, such as <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (4.5 g every six hours), or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (2 g every eight hours) to target <em>Capnocytophaga</em> species. If meningitis is suspected, we select meropenem over piperacillin-tazobactam because of its higher CSF penetrance. (See <a class="local">'Other encapsulated bacteria'</a> above and  <a class="medical medical_review" href="/z/d/html/98717.html" rel="external">"Capnocytophaga", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bloodborne parasites - </strong>For asplenic and hyposplenic patients with concern for babesiosis based on risk factors (eg, tick bite or transfusion in an endemic area) and compatible clinical features (eg, fever, myalgias, arthralgias, hemolytic anemia), we include treatment for this parasite in our initial antibiotic regimen. The diagnostic evaluation and treatment recommendations are the same as for patients with normal splenic function. However, severe and relapsing infections are more likely in patients with impaired splenic function, and, in some cases, exchange transfusion and longer treatment courses may be warranted. (See  <a class="medical medical_review" href="/z/d/html/113483.html" rel="external">"Babesiosis: Treatment and prevention"</a> and <a class="local">'Bloodborne parasites'</a> above.)</p><p></p><p class="bulletIndent1">The treatment of malaria in patients with impaired splenic function is the same as for patients with normal splenic function. (See  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Adjunctive therapy</span></p><p class="headingAnchor" id="H1127514291"><span class="h3">Dexamethasone for meningitis</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> may reduce neurologic complications and mortality in selected patients with bacterial meningitis. The benefits appear to be greatest in adults with <em>S. pneumoniae</em> meningitis, followed by children with <em>H. influenzae</em> meningitis.</p><p class="bulletIndent1"><span class="glyph">●</span>For asplenic and hyposplenic adults with known or suspected bacterial meningitis, we generally give adjunctive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (0.15 mg/kg every six hours) when it can be administered immediately prior to the first dose of antibiotics because of the high rates of <em>S. pneumoniae</em> infection in these patients. Delaying the administration beyond one hour following the first dose of antibiotics does not appear to provide benefit. For patients with microbiologically confirmed <em>S. pneumoniae</em> meningitis, we continue dexamethasone for a total of six days. For all others, we discontinue dexamethasone when <em>S. pneumoniae</em> meningitis has been excluded or is determined to be unlikely. (See  <a class="medical medical_review" href="/z/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For asplenic and hyposplenic children with suspected bacterial meningitis, we generally individualize the decision to give <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> because rates of <em>H. influenzae</em> meningitis are low and the benefits of adjunctive dexamethasone in children are less certain. For children with impaired splenic function with suspected bacterial meningitis, administering dexamethasone is also logistically difficult. Because antibiotics are often given immediately at the onset of fever and because dexamethasone should be given before or at the same time as antibiotics in order to be beneficial, it is infrequently used. (See  <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications"</a>.)</p><p></p><p class="headingAnchor" id="H3762615159"><span class="h3">Intravenous immune globulin</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> in patients with sepsis is controversial and not routinely recommended for the general population. However, patients with splenic dysfunction have specific deficits in antibody production, opsonization and phagocytosis of intravascular pathogens, and impaired antibody responses to vaccination. Because IVIG has the potential to offset these immune deficits [<a href="#rid67">67-69</a>], it is reasonable to give IVIG to selected patients with sepsis who have impaired splenic function.</p><p>Although practice varies, some UpToDate authors and editors favor the use of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> (1 g/kg on day 1, followed by 0.5 g/kg on days 2 and 3) in the following patients with known or suspected impaired splenic function:</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis complicated by hemodynamic instability that is nonresponsive to fluid resuscitation and/or DIC</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis with an additional immunocompromising condition (eg, patients with primary immunodeficiencies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis in patients who have not been vaccinated against <em>S. pneumoniae </em>or<em> H. influenzae</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis in patients who have low <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> levels (eg, IgG &lt;400 mg/dL)</p><p></p><p>Our <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> dosing recommendations are derived from the treatment of streptococcal toxic shock syndrome. (See  <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a> and  <a class="medical medical_review" href="/z/d/html/3169.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention", section on 'Intravenous immune globulin'</a>.)</p><p class="headingAnchor" id="H3494668585"><span class="h2">Response to treatment</span><span class="headingEndMark"> — </span>We generally monitor patients in a hospitalized setting, continue broad-spectrum antibiotics, and provide supportive care (as needed) for at least 72 hours while awaiting results of our diagnostic evaluation.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients in whom the source of infection is identified, we tailor our antibiotic regimen and treatment plan to target the source.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are well-appearing in whom no bacterial source is identified or suspected, we typically discontinue antibiotics after 72 hours of empiric therapy and provide close follow-up. Some experts continue empiric antibiotics (eg, intramuscular <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> or an oral fluoroquinolone) for a total of 7 to 10 days, particularly for patients who received antibiotics prior to blood cultures whose initial laboratory findings are consistent with early sepsis and/or for patients with known or suspected viral respiratory tract infections because of the risk for bacterial superinfection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who fail to improve with empiric therapy, we broaden our differential diagnosis to include the possibility of infection with an antibiotic-resistant organism (eg, highly penicillin-resistant or fluoroquinolone-resistant <em>S. pneumoniae</em>), infections with less common pathogens (eg, <em>Bordetella holmesii</em> or babesiosis), and complications of infection (eg, empyema or abscess) and adjust our treatment approach as needed. Unfortunately, some patients will progress to shock, multiorgan failure, and DIC despite appropriate treatment.</p><p></p><p class="headingAnchor" id="H1646859292"><span class="h2">COVID-19 considerations</span><span class="headingEndMark"> — </span>The evaluation and management of COVID-19 in patients with impaired splenic function is generally similar to patients with normal splenic function, however, the thresholds for treating COVID-19 infections in this population with monoclonal antibodies such as <a class="drug drug_general" data-topicid="131733" href="/z/d/drug information/131733.html" rel="external">sotrovimab</a> or direct-acting antiviral agents such as <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> and providing pre- and postexposure prophylaxis are lower. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'COVID-19-specific therapy'</a> and  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Monoclonal antibodies ineffective for pre-exposure prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Post-exposure management'</a>.)</p><p>While patients with impaired splenic function do not appear to be at increased risk for SARS-CoV-2 infection, the risk of developing severe disease may be higher. In one case-control study, evaluating &gt;165,000 patients with COVID-19 and 493,300 matched controls, the risk acquiring COVID-19 was similar; the risk of hospitalization and death was higher, though did not reach statistical significance (adjusted odds ratio for combined endpoint 1.44, 95% CI 0.79-2.61) [<a href="#rid70">70</a>]. There are no data to clarify whether specific SARS-CoV-2 variants have selective virulence against individuals with impaired splenic function.</p><p class="headingAnchor" id="H2789305130"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Reported mortality rates range widely from approximately 10 to 70 percent in patients with impaired splenic function and likely vary with the infecting pathogen, patient comorbidities, duration of illness prior to presentation, and compliance with the immediate administration of oral antibiotic therapy at the onset of symptoms, other factors [<a href="#rid13">13,22</a>]. With early recognition of sepsis, aggressive supportive care, and immediate administration of appropriate antibiotics, mortality can be substantially reduced and approach that observed in the general population [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H3229171785"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Key preventive measures include patient education on the risk of sepsis and strategies to decrease that risk; vaccination against <em>S. pneumoniae, H. influenzae </em>type b, <em>N. meningitidis, </em>influenza, and SARS-CoV-2;<em> </em>and prophylactic antibiotics. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a>.)</p><p class="headingAnchor" id="H3732172546"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109919.html" rel="external">"Society guideline links: Infections in asplenic patients"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/113967.html" rel="external">"Patient education: Splenectomy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3994.html" rel="external">"Patient education: Preventing infection in people with impaired spleen function (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of overwhelming infection</strong> − Patients with impaired splenic function are at risk for severe and overwhelming infection with encapsulated bacteria, bloodborne parasites, and other infections that the spleen plays a critical role in controlling. (See <a class="local">'Introduction'</a> above and <a class="local">'Role of the spleen in infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Important pathogens</strong> − <em>Streptococcus pneumoniae</em> is the most common cause of fulminant sepsis in patients with impaired splenic function, followed by <em>Haemophilus influenza</em>e and <em>Neisseria meningitidis.</em> Less common causes of severe infections and sepsis include other encapsulated bacteria such as <em>Capnocytophaga </em>spp, <em>Bordetella holmesii</em>, and bloodborne parasites, such as <em>Babesia</em> spp and <em>Plasmodium</em> spp  (<a class="graphic graphic_table graphicRef119148" href="/z/d/graphic/119148.html" rel="external">table 2</a>).<em> </em>(See <a class="local">'Important pathogens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever as an early sign of sepsis</strong> − Fever in a patient with impaired splenic function should be interpreted as an early sign of sepsis. Without prompt and appropriate treatment, infections in asplenic and hyposplenic patients can become fulminant and fatal within hours of symptom onset. (See <a class="local">'Clinical features'</a> above and <a class="local">'Identifying patients at risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management of fever </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Because of this risk, we advise asplenic and hyposplenic patients who develop fever to take an oral antibiotic (if on hand) AND present to the nearest emergency department immediately  (<a class="graphic graphic_table graphicRef119181" href="/z/d/graphic/119181.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef119183" href="/z/d/graphic/119183.html" rel="external">table 4</a>). (See <a class="local">'Initial triage and management'</a> above and  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a> and  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Emergency antibiotic supply'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upon arrival to the emergency department, we start empiric intravenous broad-spectrum antibiotics immediately  (<a class="graphic graphic_table graphicRef119150" href="/z/d/graphic/119150.html" rel="external">table 5</a>). For most asplenic and hyposplenic patients, we give <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus either <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>. Administration of antibiotics should <strong>not</strong> be delayed in order to perform diagnostic studies, including lumbar puncture. (See <a class="local">'Initial triage and management'</a> above and <a class="local">'Empiric antibiotic selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Modifications to these regimens may be needed based on suspected source of infection, exposure history, risk for multidrug-resistant pathogens, renal dysfunction, and other patient-specific factors including antibiotic allergy. (See <a class="local">'Empiric antibiotic selection'</a> above and <a class="local">'Penicillin and cephalosporin allergy'</a> above and <a class="local">'Unusual exposures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As with other patients with sepsis, the initial evaluation should be directed at assessing the severity of infection and identifying its source  (<a class="graphic graphic_table graphicRef119151" href="/z/d/graphic/119151.html" rel="external">table 6</a>). (See <a class="local">'Initial diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Close monitoring</strong> − We generally admit asplenic and hyposplenic patients with fever and/or sepsis to hospital for at least 72 hours for close monitoring, supportive care, and empiric antibiotic treatment while the diagnostic evaluation is pending. (See <a class="local">'Response to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive measures</strong> − Key measures for preventing infection in patients with impaired splenic function include patient education; vaccination against <em>S. pneumoniae, H. influenzae </em>type b, <em>N. meningitidis,</em> SARS-CoV-2,<em> </em>and influenza;<em> </em>and antibiotic prophylaxis. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hosea SW, Brown EJ, Hamburger MI, Frank MM. Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 1981; 304:245.</a></li><li class="breakAll">Gilsdorf JR. Infections in asplenic patients. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8, Bennett JE, Dolin R, Blaser MJ (Eds), Elsevier, Philadelphia 2015.</li><li><a class="nounderline abstract_t">Borges da Silva H, Fonseca R, Pereira RM, et al. Splenic Macrophage Subsets and Their Function during Blood-Borne Infections. Front Immunol 2015; 6:480.</a></li><li><a class="nounderline abstract_t">Kanhutu K, Jones P, Cheng AC, et al. Spleen Australia guidelines for the prevention of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand. Intern Med J 2017; 47:848.</a></li><li><a class="nounderline abstract_t">Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011; 378:86.</a></li><li><a class="nounderline abstract_t">Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med 2009; 151:546.</a></li><li><a class="nounderline abstract_t">Kristinsson SY, Gridley G, Hoover RN, et al. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 2014; 99:392.</a></li><li><a class="nounderline abstract_t">Tan KH. Fulminating pneumococcal septicaemia and meningitis in an adult twenty years after splenectomy for a ruptured spleen. Neth J Surg 1982; 34:222.</a></li><li><a class="nounderline abstract_t">Kyaw MH, Holmes EM, Toolis F, et al. Evaluation of severe infection and survival after splenectomy. Am J Med 2006; 119:276.e1.</a></li><li><a class="nounderline abstract_t">Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg 1991; 78:1031.</a></li><li><a class="nounderline abstract_t">Chong J, Jones P, Spelman D, et al. Overwhelming post-splenectomy sepsis in patients with asplenia and hyposplenia: a retrospective cohort study. Epidemiol Infect 2017; 145:397.</a></li><li><a class="nounderline abstract_t">Luoto TT, Pakarinen MP, Koivusalo A. Long-term outcomes after pediatric splenectomy. Surgery 2016; 159:1583.</a></li><li><a class="nounderline abstract_t">Theilacker C, Ludewig K, Serr A, et al. Overwhelming Postsplenectomy Infection: A Prospective Multicenter Cohort Study. Clin Infect Dis 2016; 62:871.</a></li><li><a class="nounderline abstract_t">Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect 2001; 43:182.</a></li><li><a class="nounderline abstract_t">Sakran W, Levin C, Kenes Y, et al. Clinical spectrum of serious bacterial infections among splenectomized patients with hemoglobinopathies in Israel: a 37-year follow-up study. Infection 2012; 40:35.</a></li><li><a class="nounderline abstract_t">Adriani KS, Brouwer MC, van der Ende A, van de Beek D. Bacterial meningitis in adults after splenectomy and hyposplenic states. Mayo Clin Proc 2013; 88:571.</a></li><li><a class="nounderline abstract_t">Ishikawa T, Kubota T, Horigome R, et al. Prevalence of Howell-Jolly bodies caused by partial splenic embolization for portal hypertension. Intern Med 2013; 52:1765.</a></li><li><a class="nounderline abstract_t">Nakagami Y, Uchino K, Okada H, et al. Potential role of Howell-Jolly bodies in identifying functional hyposplenism: a prospective single-institute study. Int J Hematol 2020; 112:544.</a></li><li><a class="nounderline abstract_t">Tominaga GT, Simon FJ Jr, Dandan IS, et al. Immunologic function after splenic embolization, is there a difference? J Trauma 2009; 67:289.</a></li><li><a class="nounderline abstract_t">Lammers AJ, de Porto AP, Bennink RJ, et al. Hyposplenism: comparison of different methods for determining splenic function. Am J Hematol 2012; 87:484.</a></li><li><a class="nounderline abstract_t">Chaikof EL, McCabe CJ. Fatal overwhelming postsplenectomy infection. Am J Surg 1985; 149:534.</a></li><li><a class="nounderline abstract_t">Morgan TL, Tomich EB. Overwhelming post-splenectomy infection (OPSI): a case report and review of the literature. J Emerg Med 2012; 43:758.</a></li><li><a class="nounderline abstract_t">Sawmiller CJ, Dudrick SJ, Hamzi M. Postsplenectomy Capnocytophaga canimorsus sepsis presenting as an acute abdomen. Arch Surg 1998; 133:1362.</a></li><li><a class="nounderline abstract_t">Wojtowicz JM, Longden Jones G. Streptococcus pneumoniae-induced purpura fulminans in a woman with functional asplenia. CJEM 2014; 16:339.</a></li><li><a class="nounderline abstract_t">Rizzo M, Magro G, Castaldo P. OPSI (overwhelming postsplenectomy infection) syndrome: a case report. Forensic Sci Int 2004; 146 Suppl:S55.</a></li><li><a class="nounderline abstract_t">White C, Guarascio AJ, Draper HM. Fatal purpura fulminans and septic shock in asplenic patient with Streptococcus pneumoniae bacteremia. J Am Pharm Assoc (2003) 2014; 54:88.</a></li><li><a class="nounderline abstract_t">Shahani L, Khardori N. Overwhelming Capnocytophaga canimorsus infection in a patient with asplenia. BMJ Case Rep 2014; 2014.</a></li><li><a class="nounderline abstract_t">Fogarty AB, Small JO, Colville J. Postsplenectomy pneumococcal septicaemia resulting in gangrene of the extremities. Ulster Med J 1991; 60:117.</a></li><li><a class="nounderline abstract_t">McCavit TL, Xuan L, Zhang S, et al. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer 2012; 58:945.</a></li><li><a class="nounderline abstract_t">Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428.</a></li><li><a class="nounderline abstract_t">Marrie TJ, Tyrrell GJ, Majumdar SR, Eurich DT. Asplenic patients and invasive pneumococcal disease-how bad is it these days? Int J Infect Dis 2016; 51:27.</a></li><li><a class="nounderline abstract_t">Loggie BW, Hinchey EJ. Does splenectomy predispose to meningococcal sepsis? An experimental study and clinical review. J Pediatr Surg 1986; 21:326.</a></li><li><a class="nounderline abstract_t">Zahid MF, Bains APS. Rapidly fatal Klebsiella pneumoniae sepsis in a patient with pyruvate kinase deficiency and asplenia. Blood 2017; 130:2906.</a></li><li><a class="nounderline abstract_t">Tartof SY, Gounder P, Weiss D, et al. Bordetella holmesii bacteremia cases in the United States, April 2010-January 2011. Clin Infect Dis 2014; 58:e39.</a></li><li><a class="nounderline abstract_t">Livovsky DM, Leibowitz D, Hidalgo-Grass C, et al. Bordetella holmesii meningitis in an asplenic patient with systemic lupus erythematosus. J Med Microbiol 2012; 61:1165.</a></li><li><a class="nounderline abstract_t">Khawari AA, Myers JW, Ferguson DA Jr, Moorman JP. Sepsis and meningitis due to Capnocytophaga cynodegmi after splenectomy. Clin Infect Dis 2005; 40:1709.</a></li><li><a class="nounderline abstract_t">Chiappa V, Chang CY, Sellas MI, et al. Case records of the Massachusetts General Hospital. Case 10-2014. A 45-year-old man with a rash. N Engl J Med 2014; 370:1238.</a></li><li><a class="nounderline abstract_t">Butler T. Capnocytophaga canimorsus: an emerging cause of sepsis, meningitis, and post-splenectomy infection after dog bites. Eur J Clin Microbiol Infect Dis 2015; 34:1271.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17-1999. A 42-year-old asplenic man with gram-negative sepsis. N Engl J Med 1999; 340:1819.</a></li><li><a class="nounderline abstract_t">Pittet LF, Posfay-Barbe KM. Bordetella holmesii: Still Emerging and Elusive 20 Years On. Microbiol Spectr 2016; 4.</a></li><li><a class="nounderline abstract_t">Mir-Cros A, Codina G, Martín-Gómez MT, et al. Emergence of Bordetella holmesii as a Causative Agent of Whooping Cough, Barcelona, Spain. Emerg Infect Dis 2017; 23:1856.</a></li><li><a class="nounderline abstract_t">Fong W, Timms V, Holmes N, Sintchenko V. Detection and incidence of Bordetella holmesii in respiratory specimens from patients with pertussis-like symptoms in New South Wales, Australia. Pathology 2018; 50:322.</a></li><li><a class="nounderline abstract_t">Shepard CW, Daneshvar MI, Kaiser RM, et al. Bordetella holmesii bacteremia: a newly recognized clinical entity among asplenic patients. Clin Infect Dis 2004; 38:799.</a></li><li><a class="nounderline abstract_t">Pittet LF, Emonet S, Schrenzel J, et al. Bordetella holmesii: an under-recognised Bordetella species. Lancet Infect Dis 2014; 14:510.</a></li><li><a class="nounderline abstract_t">Li CK, Shing MM, Chik KW, et al. Klebsiella pneumoniae meningitis in thalassemia major patients. Pediatr Hematol Oncol 2001; 18:229.</a></li><li><a class="nounderline abstract_t">Mareedu N, Schotthoefer AM, Tompkins J, et al. Risk Factors for Severe Infection, Hospitalization, and Prolonged Antimicrobial Therapy in Patients with Babesiosis. Am J Trop Med Hyg 2017; 97:1218.</a></li><li><a class="nounderline abstract_t">O'Connell S, Lyons C, Abdou M, et al. Splenic dysfunction from celiac disease resulting in severe babesiosis. Ticks Tick Borne Dis 2017; 8:537.</a></li><li><a class="nounderline abstract_t">Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46:370.</a></li><li><a class="nounderline abstract_t">Browne S, Ryan Y, Goodyer M, Gilligan O. Fatal babesiosis in an asplenic patient. Br J Haematol 2010; 148:494.</a></li><li><a class="nounderline abstract_t">Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. Babesiosis. Infect Dis Clin North Am 2015; 29:357.</a></li><li><a class="nounderline abstract_t">Karkoska K, Louie J, Appiah-Kubi AO, et al. Transfusion-transmitted babesiosis leading to severe hemolysis in two patients with sickle cell anemia. Pediatr Blood Cancer 2018; 65.</a></li><li><a class="nounderline abstract_t">Gubernot DM, Nakhasi HL, Mied PA, et al. Transfusion-transmitted babesiosis in the United States: summary of a workshop. Transfusion 2009; 49:2759.</a></li><li><a class="nounderline abstract_t">Manian FA, Barshak MB, Lowry KP, et al. CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 27-2016. N Engl J Med 2016; 375:981.</a></li><li><a class="nounderline abstract_t">Demar M, Legrand E, Hommel D, et al. Plasmodium falciparum malaria in splenectomized patients: two case reports in French Guiana and a literature review. Am J Trop Med Hyg 2004; 71:290.</a></li><li><a class="nounderline abstract_t">Chotivanich K, Udomsangpetch R, McGready R, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis 2002; 185:1538.</a></li><li><a class="nounderline abstract_t">Lipman HM. Preventing severe infection after splenectomy: risk of malaria and meningitis increases with asplenia. BMJ 2005; 331:576.</a></li><li><a class="nounderline abstract_t">Looareesuwan S, Suntharasamai P, Webster HK, Ho M. Malaria in splenectomized patients: report of four cases and review. Clin Infect Dis 1993; 16:361.</a></li><li><a class="nounderline abstract_t">Han XY, Lin P, Amin HM, Ferrajoli A. Postsplenectomy cytomegaloviral mononucleosis: marked lymphocytosis, TCRgamma gene rearrangements, and impaired IgM response. Am J Clin Pathol 2005; 123:612.</a></li><li><a class="nounderline abstract_t">Hasegawa T, Oshima Y, Yamamoto M, Sato Y. Fatal cytomegalovirus infection following cardiac surgery in a neonate with asplenia. Pediatr Int 2016; 58:1367.</a></li><li><a class="nounderline abstract_t">Xu F, Dai CL, Wu XM, Chu P. Overwhelming postsplenectomy infection due to Mycoplasma pneumoniae in an asplenic cirrhotic patient: case report. BMC Infect Dis 2011; 11:162.</a></li><li><a class="nounderline abstract_t">Sheng CF, Liu BY, Zhang HM, Zheng X. Overwhelming postsplenectomy infection. Genet Mol Res 2015; 14:2702.</a></li><li><a class="nounderline abstract_t">Rabinstein A, Tikhomirov V, Kaluta A, et al. Recurrent and prolonged fever in asplenic patients with human granulocytic ehrlichiosis. QJM 2000; 93:198.</a></li><li><a class="nounderline abstract_t">Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infection--an update. Crit Care Med 1999; 27:836.</a></li><li><a class="nounderline abstract_t">Lynch AM, Kapila R. Overwhelming postsplenectomy infection. Infect Dis Clin North Am 1996; 10:693.</a></li><li><a class="nounderline abstract_t">Watt KM, Massaro MM, Smith B, et al. Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis. Pediatr Infect Dis J 2012; 31:197.</a></li><li><a class="nounderline abstract_t">Wirth S, Emil SGS, Engelis A, et al. Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study. Pediatr Infect Dis J 2018; 37:e207.</a></li><li><a class="nounderline abstract_t">Nakamura K, Doi K, Okamoto K, et al. Specific antibody in IV immunoglobulin for postsplenectomy sepsis. Crit Care Med 2013; 41:e163.</a></li><li><a class="nounderline abstract_t">Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 2001; 7:657.</a></li><li><a class="nounderline abstract_t">Wang J, McQuilten ZK, Wood EM, Aubron C. Intravenous immunoglobulin in critically ill adults: When and what is the evidence? J Crit Care 2015; 30:652.e9.</a></li><li><a class="nounderline abstract_t">Bojesen AB, Lund A, Mortensen FV, Kirkegård J. Splenectomy and risk of COVID-19 infection, hospitalisation, and death. Infect Dis (Lond) 2021; 53:678.</a></li></ol></div><div id="topicVersionRevision">Topic 1404 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7442756" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Opsonic requirements for intravascular clearance after splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7442756" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Opsonic requirements for intravascular clearance after splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26441984" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Splenic Macrophage Subsets and Their Function during Blood-Borne Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27925427" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Spleen Australia guidelines for the prevention of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474172" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Post-splenectomy and hyposplenic states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841456" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24056815" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7162682" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fulminating pneumococcal septicaemia and meningitis in an adult twenty years after splenectomy for a ruptured spleen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490477" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evaluation of severe infection and survival after splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1933181" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Postsplenectomy sepsis and its mortality rate: actual versus perceived risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27776576" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Overwhelming post-splenectomy sepsis in patients with asplenia and hyposplenia: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26832988" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term outcomes after pediatric splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26703862" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Overwhelming Postsplenectomy Infection: A Prospective Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11798256" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk of infection and death among post-splenectomy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21866338" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical spectrum of serious bacterial infections among splenectomized patients with hemoglobinopathies in Israel: a 37-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23628588" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bacterial meningitis in adults after splenectomy and hyposplenic states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23955609" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence of Howell-Jolly bodies caused by partial splenic embolization for portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32572828" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Potential role of Howell-Jolly bodies in identifying functional hyposplenism: a prospective single-institute study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667881" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immunologic function after splenic embolization, is there a difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22488175" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hyposplenism: comparison of different methods for determining splenic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3985292" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatal overwhelming postsplenectomy infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22726665" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Overwhelming post-splenectomy infection (OPSI): a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865657" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Postsplenectomy Capnocytophaga canimorsus sepsis presenting as an acute abdomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25060091" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Streptococcus pneumoniae-induced purpura fulminans in a woman with functional asplenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15639588" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : OPSI (overwhelming postsplenectomy infection) syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24407746" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fatal purpura fulminans and septic shock in asplenic patient with Streptococcus pneumoniae bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24759159" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Overwhelming Capnocytophaga canimorsus infection in a patient with asplenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1853490" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Postsplenectomy pneumococcal septicaemia resulting in gangrene of the extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793185" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17479937" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27590561" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Asplenic patients and invasive pneumococcal disease-how bad is it these days?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3701550" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Does splenectomy predispose to meningococcal sepsis? An experimental study and clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29284613" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapidly fatal Klebsiella pneumoniae sepsis in a patient with pyruvate kinase deficiency and asplenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092805" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bordetella holmesii bacteremia cases in the United States, April 2010-January 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22556329" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bordetella holmesii meningitis in an asplenic patient with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15889384" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sepsis and meningitis due to Capnocytophaga cynodegmi after splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24670171" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Case records of the Massachusetts General Hospital. Case 10-2014. A 45-year-old man with a rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25828064" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Capnocytophaga canimorsus: an emerging cause of sepsis, meningitis, and post-splenectomy infection after dog bites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362827" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17-1999. A 42-year-old asplenic man with gram-negative sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27227292" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bordetella holmesii: Still Emerging and Elusive 20 Years On.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29052540" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Emergence of Bordetella holmesii as a Causative Agent of Whooping Cough, Barcelona, Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29455870" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Detection and incidence of Bordetella holmesii in respiratory specimens from patients with pertussis-like symptoms in New South Wales, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999621" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bordetella holmesii bacteremia: a newly recognized clinical entity among asplenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24721229" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bordetella holmesii: an under-recognised Bordetella species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11293293" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Klebsiella pneumoniae meningitis in thalassemia major patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28722598" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Risk Factors for Severe Infection, Hospitalization, and Prolonged Antimicrobial Therapy in Patients with Babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286145" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Splenic dysfunction from celiac disease resulting in severe babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181735" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Persistent and relapsing babesiosis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19664008" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Fatal babesiosis in an asplenic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999229" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28766838" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transfusion-transmitted babesiosis leading to severe hemolysis in two patients with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821952" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transfusion-transmitted babesiosis in the United States: summary of a workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27602671" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 27-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381808" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Plasmodium falciparum malaria in splenectomized patients: two case reports in French Guiana and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992295" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Central role of the spleen in malaria parasite clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150776" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Preventing severe infection after splenectomy: risk of malaria and meningitis increases with asplenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8452947" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Malaria in splenectomized patients: report of four cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743745" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Postsplenectomy cytomegaloviral mononucleosis: marked lymphocytosis, TCRgamma gene rearrangements, and impaired IgM response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28008743" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fatal cytomegalovirus infection following cardiac surgery in a neonate with asplenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21651767" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Overwhelming postsplenectomy infection due to Mycoplasma pneumoniae in an asplenic cirrhotic patient: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25867418" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Overwhelming postsplenectomy infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10751242" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Recurrent and prolonged fever in asplenic patients with human granulocytic ehrlichiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10321679" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prevention and management of overwhelming postsplenectomy infection--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8958164" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Overwhelming postsplenectomy infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22016080" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29356761" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23863254" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Specific antibody in IV immunoglobulin for postsplenectomy sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843905" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevention and management of infections in patients without a spleen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25702845" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intravenous immunoglobulin in critically ill adults: When and what is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939582" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Splenectomy and risk of COVID-19 infection, hospitalisation, and death.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
